RUNX2 and prostate cancer: Prior studies indicate that RUNX2 is required for osteolytic lesions of either breast cancer or prostate cancer cells upon intra-tibial injection and cell culture models indicate that RUNX2 expression stimulates cell invasion [8,11,12,21].